Clearmind Medicine (NASDAQ:CMND) Stock Set to Reverse Split on Monday, October 5th

Clearmind Medicine Inc. (NASDAQ:CMND)’s stock is set to reverse split on Monday, October 5th. The 1-8 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.

Clearmind Medicine Trading Down 11.1%

CMND stock traded down $0.09 during mid-day trading on Thursday, reaching $0.72. 219,393 shares of the stock traded hands, compared to its average volume of 1,131,579. Clearmind Medicine has a one year low of $0.71 and a one year high of $480.00. The stock has a market capitalization of $730,116.00, a PE ratio of -0.02 and a beta of 0.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 4.31. The business has a 50-day moving average price of $1.39 and a two-hundred day moving average price of $3.88.

Clearmind Medicine (NASDAQ:CMND) last released its earnings results on Thursday, September 10th. The company reported ($0.57) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th.

About Clearmind Medicine

Clearmind Medicine Inc is a biotechnology company focused on developing psychedelic-derived therapeutics for behavioral and mental health disorders. Its research programs are designed to address conditions with significant unmet medical needs, including alcohol use disorder and binge-related behaviors.

The company’s pipeline includes investigational compounds based on novel psychedelic molecules, including 5-methoxy-2-aminoindane (MEAI). Clearmind is studying these compounds for their potential to reduce harmful consumption patterns and support improved mental health outcomes.